The ongoing search for biomarkers of response to systemic therapy in advanced hepatocellular carcinoma. KU Leuven
The combination of immune checkpoint inhibitors with anti-angiogenic agents has revolutionized the treatment landscape of advanced hepatocellular carcinoma (HCC). As more therapies become available, each effective in a, yet undefined, subgroup of patients, managing advanced HCC well has become increasingly complex. With the fast pace at which the landscape evolves and the lack of data on head to head comparisons of novel regimens, an ...